Charles Jost, MD
Cardiovascular Disease · Mesa, AZNPI 1134121874
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (41.2%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 50 manufacturers reported payments, led by Medtronic at 29.8% of the total. Reporting peaked in 2022 at $19,324 and has fallen 81.6% since, to $3,551 in 2025. Among cardiovascular disease clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 599 payments — averaging $83.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$15K
- Philips North America LLC$15K
- Impulse Dynamics (USA) Inc.$11K
- Novartis$994
- Merck$927
- Abbott$869
- plus $6K from 44 others
Across 75 payments — averaging $4327.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Impulse Dynamics (USA) Inc.$268K
- Cvrx, Inc.$37K
- Endologix LLC$20K
What the payments were for
- Consulting fees$12,60025%
- Speaking & faculty fees$16,40033%
- Travel & lodging$1890%
- Food & beverage$20,52941%
- Education$1560%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- (9520) IGT Devices Undivided$12,100
- OPTIMIZER$11,367
- HawkOne$8,856
- OPTIMIZER SMART SYSTEM$1,076
- SilverHawk$931
- Abre$785
- ELCA$770
- Micra$561
- Admiral Xtreme$383
- Turbo Elite$343
- LINQ II$323
- Confirm Rx$269
- Trilogy 100$247
- VERQUVO$226
- IGT D Coronary$224
- Inspire$211
- CapSure Sense$159
- SpiderFX$153
- CARDIOMEMS$150
- Navicross$143
How this compares
$49,874 in reported general payments places this provider in the 90th percentile of 423 cardiovascular disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 219 | $278,377 |
| XareltoRivaroxaban | 109 | $112,705 |
| Repatha SureclickEvolocumab | 114 | $111,968 |
| EntrestoSacubitril/Valsartan | 39 | $50,044 |
| BrilintaTicagrelor | 53 | $38,958 |
| OzempicSemaglutide | 15 | $26,287 |
| FarxigaDapagliflozin Propanediol | 17 | $21,834 |
| Praluent PenAlirocumab | 20 | $20,508 |
| VascepaIcosapent Ethyl | 11 | $10,667 |
| Atorvastatin Calcium | 780 | $9,326 |
| ClopidogrelClopidogrel Bisulfate | 689 | $8,421 |
| LivaloPitavastatin Calcium | 17 | $7,716 |
| NexlizetBempedoic Acid/Ezetimibe | 13 | $7,088 |
| Metoprolol Succinate | 309 | $4,373 |
| Ranolazine ErRanolazine | 14 | $3,557 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $164 | $278,377219 claims |
| Johnson & JohnsonXarelto | $490 | $112,705109 claims |
| AstraZenecaBrilinta, Farxiga | $298 | $60,79170 claims |
| NovartisEntresto | $994 | $50,04439 claims |
| Novo NordiskOzempic | $171 | $26,28715 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $23 | $7,71617 claims |
| Esperion Therapeutics, Inc.Nexlizet | $63 | $7,08813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 423 cardiovascular disease providers in Arizona.
Other cardiovascular disease in Mesa
- Andrew KaplanMesa$204K
- Rodrigo ChanMesa$81K
- Edgardo Zavala AlarconMesa$72K
- Amy DalimanMesa$67K
- Santosh DesaiMesa$26K
- Ashish GuptaPhoenix$1.1M
- Rajkumar SugumaranPhoenix$957K
- Krishnaswami VijayaraghavanScottsdale$927K
- Steven MottlTucson$340K
- Paul UnderwoodScottsdale$259K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.